Laura Towart, Founder and CEO at Vivan Therapeutics, shared a post by Gedeon Richter on LinkedIn, adding:
“This week’s announcement marks a major milestone for Celmatix Therapeutics and for the broader women’s health ecosystem – and landing in International Women’s Day week makes it feel all the more meaningful.
Gedeon Richter has acquired Celmatix’s women’s health discovery portfolio: three programs spanning an oral treatment to make fertility procedures more convenient, a non-hormonal therapy targeting pain and inflammation in endometriosis, and early-stage antibodies aimed at improving control of ovarian function. Seeing these assets move into Richter’s pipeline – with development led by their women’s health R/D hub in Belgium – gives me real confidence in what comes next.
I co-founded Celmatix in 2009 and served as CEO in the earliest chapter: building the company out of grad school with a singular mission – bringing the promise of personalized medicine to women’s health.
My co-founder Piraye Beim and I shaped the foundational scientific and IP strategy, secured early grant support and first institutional funding, and assembled the team that made the platform possible. The genomics-linked fertility dataset we built is a rare and powerful scientific asset – one I’m confident will continue to drive translational advances for years to come.
Over the years I’ve held many roles at Celmatix – CEO, Chief Strategic Officer, Chairman, Director, and Investor. I’ve not been involved in the business for the past few years, so I’m watching this moment from the outside – but what I feel most strongly is pride in what the Celmatix team has built, and real optimism for what this moment can unlock for women’s health R/D. Congrats to everyone who contributed over the years.
Personalized medicine has always been my true passion. I’ve carried the lessons of this journey – including hard-won ones about co-founder relations, expansion, governance, and exit timing – into what I’m building now at Vivan Therapeutics where I am committed to pioneering personalized cancer therapeutics. This milestone only deepens my conviction that science, when given the right foundation and dedication, can drive change in medicine.”
Quoting Gedeon Richter‘s post:
“Richter Acquires Discovery Portfolio of Celmatix.
We are thrilled to announce the acquisition of the women’s health discovery portfolio of Celmatix Inc., a US-based biotech focused on translating advances in female biology into novel therapeutics.
The acquisition brings three promising programs: an oral treatment designed to make fertility procedures more convenient for patients, a potential non-hormonal therapy targeting both pain and inflammation in endometriosis, and innovative early-stage antibodies aimed at improving control of ovarian function. Together, these assets further strengthen Richter’s development pipeline in fertility, endometriosis and ovarian ageing.
As women’s health has long been overlooked despite major unmet medical needs, advancing research in key therapeutic areas such as endometriosis, ovarian ageing and infertility is essential. By strengthening our pipeline and broadening the scope of our scientific platform and innovation engine, we are taking further steps toward our ambition to become a thought leader in women’s healthcare and to deliver innovative solutions that can meaningfully improve the lives of millions of women worldwide
– said Dr. Péter Turek, Head of Women’s Healthcare Business Unit at Richter.
Development will be led by Richter’s women’s health R&D hub in Belgium, reinforcing its role as a center of excellence within the company’s global innovation network.
Read the full announcement on our website.”
Other articles on OncoDaily.